Introduction
A major focus of cancer immunotherapy has been stimulating patients' CD8 + cytolytic T cells to kill tumor cells. In one treatment modality, tumor-infiltrating leukocytes (TILs) are isolated from the patient, activated ex vivo and infused back into the same patient. Such adoptive cell therapy (ACT) has shown clinical benefit in treating melanoma (1) . In another treatment modality, DC based vaccines are used to stimulate the patients' endogenous anti-tumor immune response, and recently has been approved for treating prostate cancer (2) . Despite these successes, a major hurdle to widespread use of these and other treatments utilizing CD8 + T cells is the tolerizing environment within the tumor tissue (1), which rapidly inactivates TILs and render the therapies ineffective.
T cell activation and function is regulated by both costimulatory and inhibitory signals. In concert with peptide MHC (pMHC) and T cell receptor (TCR) signaling, additional receptors on T cells promote or negate expansion, differentiation, and survival (3) . Programmed death-1 (PD-1) expressed on activated T cells inhibits T cell function upon engagement with its ligand, PDLigand 1 (PD-L1). PD-L1 is expressed on tumor and/or tumor associated stroma, and sites of immune privilege, and is considered a promising candidate for checkpoint blockade in tumor immunotherapy (4) . Indeed, blockade of PD-L1 along with adoptive transfer of tumor specific T cells, delays tumor growth in preclinical melanoma models (5) . Among costimulatory molecules, engagement of CD28 on T cells with CD80 and CD86 on antigen presenting cells (APCs) promotes activation of both naïve and memory T cells (3) . Specific to anti-tumor responses, enforced expression of CD80 and/or CD86 on tumor cells stimulates their destruction by the immune system (6), a strategy of cancer immunotherapy that has been tested in clinical trials (7) .
The TNF family contains a diverse array of molecules critical for positively regulating T cell function, including the CD27/CD70 and 4-1BB/4-1BBL receptor ligand pairs, expressed on T cells/APCs, respectively (8) . Overexpression of CD70 in transgenic mice enhances priming of T cells, leading to rejection of EL-4 thymomas that express the nucleoprotein (NP) model antigen (9) . Similarly, in vivo stimulation of clonotypic T cells with an anti-4-1BB antibody promotes T cell rejection of established murine plasmacytoma tumors (10) .
In our study of CD8 (12) expressing high levels of PD-1, analogous to TILs in patients. Importantly, we have found that antigen-loaded bone marrow-derived DCs (BMDCs), when injected intraprostatically, delay the rapid tolerance induction of effector 2C T cells as they initially infiltrate the tumor tissue (13) . In addition, when antigen-loaded BMDCs are injected after initial tolerance induction, they refunctionalize the persisting tolerized 2C T cells in the tumor tissue.
These previous studies set the stage to define molecular interactions that are required for prostate tumor-mediated T cell tolerance induction and DC-mediated delay and reactivation of tolerized T cells in the prostate tumor microenvironment.
In this study, we have evaluated the role of PD-1/PD-L1 interaction in T cell tolerance induction in the prostate tumor tissue and the role of CD80, CD86, 4-1BBL, and CD70 in DCmediated delay of T cell tolerance induction and refunctionalization of tolerized T cells in the prostate tumor tissue. Our results show that despite the high levels of PD-1 expression by prostate-infiltrating T cells and PD-L1 expression in the prostate, blocking PD-1/PD-L1 interaction has no effect on T cell tolerance induction in the prostate tumor tissue. While CD70 is required for DC-mediated delay of T cell tolerance induction, CD80 and CD86 are required for refunctionalizing the tolerized T cells in the prostate tumor tissue. These findings show that different costimulatory signals are required to overcome tumor tolerizing signals during the initial tolerance induction and reactivation of previously tolerized T cells. They also suggest approaches to overcome the tolerizing tumor environment to achieve more efficacious cancer immunotherapy by ACT and DC vaccination.
Materials and Methods

Mice, Adoptive Transfer and Influenza Infection
TRP-SIY mice were generated as previously described (11) . 2C TCR transgenic mice were maintained on C57BL/6 and RAG1 -/-backgrounds (2C/RAG mice). CD86, and CD80/CD86 knockout mice on the C57BL/6 background were from Jackson Laboratories (Bar Harbor, ME).
CD80, PD-L1 knockout and TRAMP mice were bred in house. Where indicated, mice were retroorbitally injected with 1.5x10 6 naïve 2C cells from 2C/RAG mice and were intranasally infected with 100 pfu WSN-SIY influenza A virus. All experiments were approved by the Committee on Animal Care (CAC) at Massachusetts Institute of Technology.
Generation of Bone Marrow-Derived DCs (BMDCs) and Intraprostatic Injection
Bone marrow was collected from the femurs of C57BL/6 mice, or indicated knockout mice.
Cells were resuspended at 2x10 5 cells/mL in RPMI plus 10%FCS, 50μM 2-mercaptoethanol, 4mM L-glutamine and 100U/mL-100ug/mL penicillin-streptomycin supplemented 1:30 with the supernatant from J5 cells secreting GM-CSF. Cells were washed and media changed on day 2 and 5, 1μg/mL LPS was added on day 6, and cells were harvested on day 7. Where indicated, BMDCs were loaded with 1μg/mL SIY peptide for 1hr at 37°C and/or were labeled for 10 min at 37°C with 5µM CFSE (Invitrogen) in PBS plus 0.1% BSA on the day of harvest. For blocking experiments, 1x10 6 cell/mL were incubated in 10 μg/mL of F(ab') 2 of indicated antibodies for 2.5 hours on ice, as previously described (14) . BMDCs were rinsed and resuspended at 1x10 
Cells and Flow Cytometry
Single cell suspensions were prepared from lymphoid tissues by grinding them between frosted glass slides and filtering the suspensions through 70µm nylon mesh. Prostate tissues were digested with 2µg/mL collagenase A (Roche) and 170U/mL DNase I (Sigma-Aldrich) in RPMI 1640 plus 10% FCS for 1hr at 37ºC. Digested samples were then ground between frosted glass slides and filtered through 70µm nylon mesh. Intracellular IFN-γ staining was performed with a BD Cytofix/Cytoperm Kit (BD Biosciences). Recovered cells were restimulated with 1μg/mL SIY peptide for 4hr at 37°C in the presence of BD GolgiPlug containing brefeldin A. Surface antigens were stained, dead cells were identified using a LIVE/DEAD Fixable Red Dead Cell Stain Kit (Invitrogen), and all cells were fixed and permeabilized. Samples were then stained with a PE-conjugated anti-IFN-γ antibody (BD Pharmingen). Gates were set using a panel of fluorescent minus one controls. Statistical analysis was conducted using a Student's t test and data considered significant if p<0.05.
Immunohistochemistry
Prostate glands were excised from mice, flash frozen in OCT compound (Tissue-Tek, Sakura, Torrance, CA) and cyrosectioned at 10 μM by the Koch Institute Histology Core Facility.
Sections were fixed with acetone and stained with Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). Visualization of PD-L1 staining was carried out with 3,3'-diaminobenzidine (DAB) substrate (Vector Laboratories) and counterstained with eosin (SigmaAldrich, St. Louis, MO). Images were acquisitioned using a Zeiss Axioplan II microscope, using Zeiss 25x (0.8) lenses and a QImaging MicroPublisher 5.0 color camera. Images were captured using Openlab 5.5 (Improvision, PerkinElmer), and analyzed using ImageJ (US National Institutes of Health).
Antibodies and F(ab') 2 Production
Fluorescently labeled Anti-Thy1.1 (Clone OX-7), CD27 (LG.3A10), CD11c (N418), CD28 Laboratories. 2C TCR was stained using a biotin-conjugated clonotypic 1B2 antibody detected with streptavidin-APC (BioLegend). Stained cells were analyzed using a FACSCalibur or LSR II (BD Biosciences) instrument, and the data was processed using FlowJo software (Tree Star).
F(ab') 2 fragments were generated from purified anti-CD70 (FR70, eBioscience), anti-4-1BBL (TKS-1, eBioscience), anti-FcR (CD16/CD32) (2.4G2-BD Pharmingen) (PMID: 6736648) using the Pierce F(ab') 2 Preparation Kit (Thermo Scientific) and concentration determined by absorbance on 280nm, as recommended. For F(ab') 2 competition experiments, 1x10 6 cell/mL were incubated in 10 μg/mL of F(ab') 2 fragment and full length fluorescently labeled antibody, followed by staining with CD11c and analysis by flow cytometry.
In Vivo Cytotoxicity Assay
In vivo cytotoxicity was performed as previously described (13) . Briefly, C57BL/6 (Thy1. 
Results
PD-1 is expressed on prostate resident T cells and PD-L1 on the prostate stroma.
To define the pathways that regulate tolerance of 2C T cells in the TRP-SIY system we assessed the expression of inhibitory receptors on the surface of 2C T cells. PD-1, Tim3, and LAG-3, individually or in combination, negatively regulate T cell responses in tumor tissues (15, 16) . T cells recovered thirteen days post transfer, (or approximately 6 days after initial infiltration into the prostate) expressed high levels of PD-1 (Fig. 1A) . Expression of PD-1 was maintained on prostate resident 2C T cells after 36 day post transfer into TRP-SIY mice (Fig. 1A) . In contrast to PD-1, prostate resident 2C T cells did not express Tim3 or LAG-3 either 13 or 36 days post transfer (Fig. 1B, 1C) . PD-L1 expression was detected on both C57BL/6-SIY and TRP-SIY prostate cells by flow cytometry (Fig. 1D ) and confirmed by histological staining of prostate tissue sections (Fig. 1E) .
Modulating the PD-1/PD-L1 axis does not improve T cell responses in TRP-SIY mice
The expression of PD-1 on 2C T cells and PD-L1 on prostate cells provides the basis for a possible role of PD-1/PD-L1 interaction in tolerance induction in the TRP-SIY system. To test this notion, we generated TRP-SIY mice on a PD-L1 
BMDCs act directly on 2C T cells in the TRP-SIY prostate
We assessed the mechanisms by which BMDCs activate 2C T cells within the prostate tissue. To (Fig. 3D) . We therefore confirmed the activity of injected BMDCs is dependent on the direct presentation of the SIY peptide to the 2C T cells. We compared the effect of injection of PBS, SIY peptide alone, or activated BMDCs that had not been pulsed with the SIY peptide on IFN-γ expression by 2C T cells in the prostate.
Injection of SIY peptide alone did not significantly stimulate IFN-γ expression by 2C T cells above control PBS injection (Fig. 3E) , suggesting that presentation of SIY by the endogenous DCs is not a major factor in reactivation of 2C T cells. Injection of activated BMDCs without being loaded with the SIY peptide in vitro stimulated a higher fraction of 2C T cells to produce IFN-γ (Fig. 3E) than PBS or SIY peptide alone. However, the effect was lesser than SIY-loaded BMDCs (compare to Fig. 2 ). The observed effect is unlikely due to non-specific effect of injected BMDCs but likely due to uptake and presentation of SIY peptide in the prostate of TRP-SIY mice where the SIY transgene is robustly expressed (11) . Taken together, these results suggest that BMDCs activate 2C T cells in the prostate tumor partly by directly engaging 2C T cells through pMHC/TCR interaction.
CD80 and CD86 are required to reactivate tolerized T cells in the prostate tumor tissue
Next, we determined cell surface molecules on BMDCs that are required for reactivating 2C T cells in addition to SIY/MHC. Upregulated upon maturation of DCs, CD80 and CD86 provide an important stimulus in the context of the TCR/peptide MHC-1 engagement (3). Specific to prostate cancer, provision of antagonistic CD80 or CD86 antibodies abrogates the immunosuppressive environment and reduces tumor growth (17) . BMDCs exhibit robust expression of CD80 and CD86 before intraprostate injection (Fig. 4A) . Therefore, we compared the effect of intraprostatic injection of SIY-loaded wild type DC and DCs deficient in CD80, CD86, or both CD80 and CD86 in TRP-SIY mice. Experiments were carried out as in (20, 21) . Similarly, CD70 functions to maintain T cell survival and proliferation in the periphery (22, 23) . Activated BMDCs express higher levels of CD70 and 4-1BBL relative to the expression on endogenous prostate DCs (Fig. 5A, compared to Fig. 3B ). We used anti-CD70 and anti-4-1BBL antibodies previously shown to block CD70/CD27 and 4-1BBL/4-1BB interactions in vivo, to define the contribution of CD70 and 4-1BB in DC-mediated delay of tolerance induction (14, 24) . To exclude possible Fc receptor (FcR)-mediated effect on the DCs, we generated F(ab') 2 fragment of each antibody lacking the Fc portion of the molecule but still retaining binding activity as assessed by the ability to compete fluorescently labeled full length antibody for cell surface binding (Fig. 5B) . As a control, we used F(ab') 2 of the antibody cocktail against FcRs CD16 and CD32 (25) . SIY-loaded BMDCs were incubated with each antibody fragment and then injected into prostate tumor tissue of TRP-SIY mice 7 days after 2C T cell transfer and WSN-SIY infection. FcR-blocking antibodies did not diminish the ability of BMDCs to stimulate prolonged IFN-γ expression by infiltrating 2C T cells (Fig. 5C ). Blocking the interaction between 4-1BB on 2C T cells and 4-1BBL on BMDCs did not impair DCs' ability to extend the IFN-γ expression by infiltrating 2C T cells. However, blockade of CD70 on BMDCs significantly reduced their ability to stimulate prolonged IFN-γ expression by infiltrating 2C T cells in the prostate (Fig.   5C ). The observed difference was not due to differential retention of anti-CD70 treated BMDCs within the prostate tissue as compared to control treated BMDCs (Fig. 5E) , consistent with previous experiments with untreated BMDCs (13) . These results show that CD70/CD27 interaction is required for DC-mediated delay of 2C T cell tolerance induction in the prostate tumor tissue. 
CD70 but not 4-1BBL is required for BMDC mediated delay in T cell tolerance
CD27 is downregulated on prostate resident T cells
The costimulatory molecules necessary to delay tolerance induction and reactivate already tolerized 2C T cells are distinct. BMDCs expressed similar levels of costimulatory molecules whether they were used to delay tolerance induction or reactivate already tolerized T cells. The functional differences between these two time points may be a result of phenotypic changes on prostate resident 2C T cells. Thus, we assessed 2C T cell expression of CD28, CD27, and 4-1BB before transfer and 13, 23, and 36 days following transfer and infection in TRP-SIY mice. CD28 expression on 2C T cells from prostate remained similar at the three different time points and was similar to that of naïve 2C T cells (Fig. 6A-6C ). The expression of 4-1BB was low on 2C T cells recovered from TRP-SIY prostate throughout the 36 days following transfer (Fig. 6B, 6C ).
CD27 was highly expressed on naïve 2C T cells (Fig. 6A) . In contrast to CD28 and 4-1BB, expression of CD27 was progressively lost from 2C T cells following infiltration into TRP-SIY prostate tissue (Fig. 6B, 6C ). To determine if CD27 downregulation is specific to the TRP-SIY prostate, we transferred 2C T cells into TRAMP and C57BL/6 mice. As shown in Figure 6D , CD27 expression on 2C T cells were also downregulated on the prostate of TRAMP and C57BL/6 mice. The observed downregulation is specific to the prostate, as the level of CD27 on 2C T cells from spleen of the same mice remained stable (Fig. 6E) . These results show that the lack of effect of anti-CD70 treatment during reactivation is correlated with the downregulation of CD27 on persisting tolerized 2C T in the prostate. 
